3xTg-AD

Reactive astrogliosis and neuronal impairment: in vitro and in vivo evidence on palmitoylethanolamide effects in a triple transgenic model of Alzheimer’s disease

More than 60-80% of dementia cases worldwide in elderly people is caused by Alzheimer’s disease (AD) (Alzheimer’s disease Facts and Figures, 2017). Histopathologically, AD is characterized by the aggregation of extracellular neuritic β-amyloid peptide that leads to the creation of senile plaques, and the production of intracellular neurofibrillary tangles caused by tau protein hyperphosphorylation (Braak et al., 1988; Merz et al., 1983).

Effect of ultramicronized-palmytoilethanolamide on astrocyte dysfunction in a triple transgenic model of Alzheimer’s disease

Alzheimer's disease (AD) is one of the most economically burdensome health conditions in current society that leads patients to functional disabilities. The main features of the disease are ?-amyloid plaques (SPs) and neurofibrillary tangles (NFTs) creation which causes neuronal and synaptic loss (Braak et al., 1988; Merz et al., 1983). During last decades, also astrocyte dysfunction and the presence of an intense inflammatory state have been considered further hallmarks of AD.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma